DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages

Acquired dermal macular hyperpigmentation

Authors: Ko Jin Quek, Junior Medical Officer, South-Western Sydney Local Health District, Sydney, NSW, Australia; Dr Monisha Gupta, Dermatologist, Sydney, Australia. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. January 2020.


What is acquired dermal macular hyperpigmentation?

Acquired dermal macular hyperpigmentation comprises three conditions:

The term acquired dermal macular hyperpigmentation is useful because the three conditions overlap. The subtypes may manifest in the same patient, and they lack clear-cut clinical and histological differences [3]. However, the hypermelanosis may have differing causes.

Acquired dermal macular hyperpigmentation

See more images of acquired macular hyperpigmentation.

Who gets acquired dermal macular hyperpigmentation?

The epidemiology of acquired dermal macular hyperpigmentation varies depending on the subtype.

It can affect any age, gender, and ethnicity, and tends to affect darker-skinned patients. Asian, Middle-Eastern, and Latin American women between the 2nd and 4th decades of life are the most frequently affected [4].

What causes acquired dermal macular hyperpigmentation?

The exact cause of acquired dermal macular hyperpigmentation is unknown. 

Proposed theories for the pathogenesis of acquired dermal macular hyperpigmentation include:

  • Genetic susceptibility
  • Exposure to ultraviolet (UV) radiation
  • Contact reaction to a chemical (up to 36% of patients were reported to have a positive patch test reaction to hair dye) [5]
  • Exposure to a drug such as hydroxychloroquine
  • A viral infection.

What are the clinical features of acquired dermal macular hyperpigmentation?

Acquired dermal macular hyperpigmentation presents with blue or brown-grey macules, which can change in size and morphology over time.

Acquired dermal macular hyperpigmentation is generally asymptomatic, although lichen planus pigmentosus is sometimes pruritic in its early phases.

What are the complications of acquired dermal macular hyperpigmentation?

No detrimental serious long-term medical complications arise from acquired dermal macular hyperpigmentation. However, it has a high impact on the quality of life in people with skin of colour due to cosmetic visibility and slow resolution.

How is acquired dermal macular hyperpigmentation diagnosed?

The diagnosis of acquired dermal macular hyperpigmentation and its subtypes are based on the cutaneous features and detailed history.

Patch testing may be indicated to exclude allergic contact dermatitis if there is a possible contact factor.

Dermoscopy is useful in the diagnosis and monitoring of acquired dermal macular hyperpigmentation. Findings may include [6]:

  • Pigmented dots, globules and diffuse areas that spare eccrine and hair follicle openings
  • Prominent normal pseudoreticular pigmentary network
  • Telangiectasia
  • Owl's eye structures.

Histological features of acquired dermal macular hyperpigmentation on skin biopsy include: 

  • Melanin and melanophages in the dermis
  • Lichenoid changes with an interface dermatitis [1,3].

What is the differential diagnosis for acquired dermal macular hyperpigmentation?

A variety of other skin conditions appear similar to acquired dermal macular hyperpigmentation, such as:

What is the treatment for acquired dermal macular hyperpigmentation?

The treatment of acquired dermal macular hyperpigmentation depends on the subtype and its duration.

Acquired dermal macular hyperpigmentation can persist for months or years, and possibly be followed by postinflammatory hyperpigmentation, or relapse [3]. 

See smartphone apps to check your skin.
[Sponsored content]

 

Related information

 

References

  1. Sasidharanpillai S, Govindan A. Yathmana Ajithkumar K, Mahadevan ST, Bindu V, Khader A, Sathi PP. Histological evaluation of acquired dermal macular hyperpigmentation, Indian Dermatol Online J 2019; 10: 542–6. PubMed Central
  2. Udompanich S, Vachiramon V. Acquired Macular Pigmentation of Unknown Etiology. J Clin Aesthet Dermatol 2019; 12: 38–46. PubMed Central
  3. Rodrigues M, Pandya AG, Bekkenk M, Parsad D, Kumarasinghe SP. Current understanding of lichen planus pigmentosus, erythema dyschromicum perstans (ashy dermatosis), and idiopathic eruptive macular pigmentation. Pigment International 2019; 6: 4–8. Journal
  4. Chang SE, Kim HW, Shin JM, Lee JH, Na JI, Roh MR, Lee JH, Lee GY, Ko JY. Clinical and histological aspect of erythema dyschromicum perstans in Korea: a review of 68 cases. J Dermatol 2015; 42: 1053–7. PubMed
  5. Bishnoi A, Vinay K, Parsad D, Handa S, Saikia UN, Sendhil Kumaran M. Contact sensitization to hair colours in acquired dermal macular hyperpigmentation: results from a patch and photo‐patch test study of 108 patients. J Eur Acad Dermatol Venereol 2019; 33: 1349–57. PubMed
  6. Vinay K, Bishnoi A, Parsad D, Saikia UN, Sendhil Kumaran M. Dermatoscopic evaluation and histopathological correlation of acquired dermal macular hyperpigmentation. Int J Dermatol 2017; 56: 1395–9. PubMed
  7. Kanwar AJ, Parsad D. Colchicine in the treatment of Lichen Planus Pigmentosus, XXIst International Pigment Cell Conference, Bordeaux, France, 2011.
  8. Al‐Mutairi N, El‐Khalawany M, Clinicopathological characteristics of lichen planus pigmentosus and its response to tacrolimus ointment: an open label, non‐randomized, prospective study, Journal of the European Academy of Dermatology and Venereology 2010; 24: 535–40. PubMed
  9. Bahadir S, Çobanoglu Ü, Çimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. International J Dermatol 2004; 43: 220–2. PubMed
  10. Kontochristopoulos G, Stavropoulos P, Panteleos D, Aroni K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol 2004; 43: 796–8. PubMed

On DermNet NZ

Books about skin diseases